MedPath

Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis

Completed
Conditions
Severe Sepsis
Interventions
Other: placebo - continuous saline NaCl 50 ml
Registration Number
NCT02026856
Lead Sponsor
Pavol Jozef Safarik University
Brief Summary

This study looked at parenteral administration of selenium to septic patients and subsequently monitored dynamic changes of selected activities of antioxidant enzymes and the development of clinical status.

Detailed Description

Patients will be divided into two groups. Se-group who received selenium supplementation during hospitalization in the form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) (Selenase, Vivax; selenium hereinafter).

The placebo group will receive continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy). Patients will be further divided into subgroups according to OI on the day of admission to ICU. The oxygenation index (OI) PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) ratio in patients will be calculated daily.

The determination of biochemical and hematological parameters of blood samples will be as a part of the routine diagnostic methods. Data collection for the Se-AOX study will be performed at two-day intervals: T1 (1st-2nd day), T2 (3rd-4th day) and T3 (5th-6th day). Kinetic methods for estimating the activities of glutathione peroxidase (GPx, E.C. 1.11.1.9), glutathione reductase (GR, E.C.1.6.4.2) will be performed using a kit (Sigma-Aldrich, Germany) and that of superoxide dismutase (SOD, E.C. 1.15.1.1) by means of the SOD-Assay Kit-WST (Fluka, Japan) following the user manual provided.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4
Inclusion Criteria
  • sepsis, severe sepsis or septic shock, APACHE II score between 19 and 24 points after admission
Exclusion Criteria
  • mechanical ventilation for less than 24h, neuromuscular disease and terminal illness were also excluding criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Placebo-OI <200placebo - continuous saline NaCl 50 mlpatients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
Se-OI> 200sodium selenite pentahydratepatients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
Placebo-OI> 200placebo - continuous saline NaCl 50 mlpatients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
Se-OI <200sodium selenite pentahydratepatients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
Primary Outcome Measures
NameTimeMethod
mortality2 years
Secondary Outcome Measures
NameTimeMethod
The oxygenation index2 years

PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen)

Trial Locations

Locations (1)

1st clinic of anesthesiology and intesive care, University hospital of Louis Pasteur

🇸🇰

Košice, Slovakia

© Copyright 2025. All Rights Reserved by MedPath